Nicotinamide-induced modification of hepatic MFO systems in tumour-bearing rats, treated with anti-cancer drugs.
Chemotherapeutic drugs like cyclophospamide (100 mg/kg b.wt.) and 5-fluorouracil (120 mg/kg b.wt.) caused significant inhibition in cytochrome P450 (cytP450)-dependent hepatic microsomal drug metabolising enzymes in rats. A similar decrease in these enzyme activities was also seen in the host liver of tumour-bearing animals. However, a non-toxic, endogenous (vitamin B3) metabolite, nicotinamide (100 mg/kg b.wt.) could effectively restore the hepatic drug metabolising enzyme levels back to control values in tumour-bearing animals treated with cyclophospamide and 5-fluorouracil.
Kamat
J P
JP
Radiation Biology and Biochemistry Division, Bhabha Atomic Research Centre, Trombay, Bombay, India.
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D003520:Cyclophosphamide / Q000494:pharmacology*; D005472:Fluorouracil / Q000494:pharmacology*; D008099:Liver / Q000187:drug effects* / Q000378:metabolism; D006899:Mixed Function Oxygenases / Q000037:antagonists & inhibitors*; D009536:Niacinamide / Q000494:pharmacology*; D004364:Pharmaceutical Preparations / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D012517:Sarcoma, Yoshida / Q000378:metabolism
D000970:Antineoplastic Agents; D004364:Pharmaceutical Preparations; D009536:Niacinamide; D003520:Cyclophosphamide; D006899:Mixed Function Oxygenases; D005472:Fluorouracil